Voquill

The AI coworker that helps pathologists work cases faster

Spring 2026ActiveHealthcareArtificial IntelligenceSaaSHealth TechSan Francisco, CA, USA

Company

Voquill is the AI coworker that helps pathologists write their case reports faster. It listens as they work the case, learns their reporting style, maximizes reimbursement codes, and produces a sign-out ready report in real-time. Pathologists bill $30–40B each year, but spend a third of their time on reporting, and lose another third of their contracted revenue to documentation gaps and billing errors. It's a massive drag on a field that's already short-staffed. We're building an agentic platform to manage every aspect of the lab and displace the billions spent on legacy management systems.

Note: This is a preliminary assessment based on limited publicly available information. We did not have access to LinkedIn profiles or live product screenshots for this analysis. We will update this entry with a more thorough review soon.

Verdict

High Signal

Market Opportunity

Pathologists bill $30–40B annually with documented revenue leakage from billing gaps and documentation inefficiencies — a quantifiable, large TAM. The ICP is crisp: pathology labs and reference laboratories (Mayo, Quest, Labcorp already named). The stated ambition to displace legacy lab management systems (LIS vendors like Sunquest, CoPathPlus, Cerner) expands the market further. B2B healthcare with clear reimbursement ROI is a strong monetization structure.

High Signal

Founder Signal

Michael Gibson spent 5 years at Techcyte rising from junior engineer to VP of Engineering managing 55 people, with AI systems deployed at Mayo Clinic and large reference labs — highly domain-specific credibility. Josiah Saunders led forward-deployed AI pathology work at the same company serving Mayo, Quest, and Labcorp, then was a founding engineer at a YC-backed company (Relay Health S22). Henry Habib founded an AI education company with 500K paying students and led AI deployments at Oliver Wyman — non-technical but brings real GTM and sales execution experience. This is an unusually strong founding team for a niche healthtech vertical.

Medium Signal

Competition

No competitor data was returned in the research, but this space has real incumbents: traditional LIS vendors (Sunquest, Beaker/Epic, CoPathPlus) and emerging AI scribes (Nuance DAX, Suki) that could expand into pathology. The founders' deep domain experience at Techcyte with actual lab deployments is a meaningful moat against generalist AI scribes, but well-funded competitors or Epic expanding their pathology modules remain credible threats.

Medium Signal

Product

No press coverage, no named customer logos, no pricing page or demo visible in research data. The product concept is well-articulated — real-time report generation, billing code optimization, agentic lab management — but there's no evidence of live deployments, revenue, or paying customers in the data provided. The description references a clear workflow pain point but reads more like a pitch than a traction story.

OverallA Tier

Voquill has one of the stronger founding teams in this batch for a deep domain play — two founders with hands-on AI pathology deployment experience at Techcyte serving Mayo Clinic, Quest, and Labcorp, plus a co-founder with a proven track record building a 500K-paying-student company. The market is real, large, and structurally underserved by legacy LIS vendors. The primary concern is the complete absence of traction data: no customers named, no revenue cited, no press — which for a team this experienced is a yellow flag that the product may still be early or they're being deliberately opaque. If they have even a handful of pilot labs, this could rate S. As-is, the team and market signal is strong enough to warrant an A, but execution proof is the missing piece.

Active Founders

Michael Gibson

Founder

Michael is the co-founder & CEO of Voquill. He spent 5 years at Techcyte, a digital pathology company, joining as a junior engineer straight out of college and rising to VP of Engineering, where he managed a team of 55. At Techcyte, he led the AI team and architected digital pathology systems deployed at Mayo Clinic and other large reference laboratories.

Henry Habib

Founder

Henry is the co-founder and COO of Voquill. Before Voquill, Henry was a Principal at Oliver Wyman, where he led large AI and automation deployments for F500 companies. He previously founded The Intelligent Worker, an AI education and training company with 500K paying students.

Josiah Saunders

Founder

Josiah is the co-founder and CTO of Voquill. He led the forward-deployed team developing an AI pathology platform for customer labs (including The Mayo Clinic, Quest, Labcorp) at Techcyte. He was previously a founding engineer at Relay Health (YC S22).

Voquill

TierA Tier

BatchSpring 2026

Team Size3

StatusActive

LocationSan Francisco, CA, USA

Disagree with this rating? Let us know

$200 GPU creditsClaim yours →